Skip to content

Aurinia Pharmaceuticals

US · AUPH #2749 by market cap Listed 1970
16.01 +0.32 +2.04%
Live - 5344 symbols - heartbeat 306s ago · 2026-10-08 08:17
Pre-market 16.05 +0.25%
After-hours 16.01 0.00%
Market cap
2.13B
P/B
3.46
EPS
2.07
Reader sentiment Are you bullish or bearish on AUPH?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 3 in the most recent period (2026/Q3).
  • Total institutional ownership fell 2.4 percentage points.

Institutional ownership

Held by institutions
64.96% -2.45pp
Institutions
334 -3
As of
2026/Q3 vs. prior period

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Holder types

Mutual Fund42.27%
Hedge Fund9.27%
VC/PE Fund6.73%
Public Company4.58%
Individual/Insider2.19%
Government Pension Fund0.77%
Private Company0.71%
Insurance Company0.38%
Family Office/Trust0.15%
Other32.95%

Top holders as of 2026-06-30

Tang Capital Management, LLC 9.80% · 13.04M sh
BlackRock 6.16% · 8.19M sh
ILJIN SNT Co., Ltd 3.75% · 4.99M sh
Goldman Sachs Asset Management, L.P. 3.67% · 4.88M sh
New Enterprise Associates, Inc. 2.98% · 3.97M sh
Two Sigma Investments, LP 2.61% · 3.47M sh
Arrowstreet Capital, Limited Partnership 2.45% · 3.26M sh
State Street Global Advisors 1.95% · 2.59M sh
Morgan Stanley 1.55% · 2.06M sh
Marshall Wace LLP 1.54% · 2.04M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 27 buys · 23 sells

NameRoleStake
Peter Greenleaf Chief Executive Officer 0.79%
Matthew Donley Executive Vice President of Operations & Strategy 0.33%
Joseph Miller Chief Financial Officer 0.26%
Stephen Robertson Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer 0.23%
David R. Jayne Independent Non-Executive Director 0.03%
Gregory Keenan Chief Medical Officer 0.02%
Jeffrey Bailey Director 0.02%
Craig Johnson Director 0.01%
Jill Leversage Independent Director 0.01%
Karen Smith Director 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-09 Stephen Robertson Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer Open Market Disposition -11,939 $15.95
2026-08-20 Stephen Robertson Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer Open Market Disposition -20,975 $16.97
2026-06-04 Gregory Keenan Chief Medical Officer Intent to Sell (Form 144) -9,593 $16.52
2026-06-03 Tina Nova Independent Director Other Derivative Acquisition +23,931 $15.67
2026-06-03 Craig Johnson Director Other Derivative Acquisition +23,931 $15.67
2026-06-03 Jeffrey Bailey Director Other Derivative Acquisition +23,931 $15.67
2026-06-03 Gregory Keenan Chief Medical Officer Intent to Sell (Form 144) -25,000 $16.34
2026-06-03 Kathleen Goetz -- Other Derivative Acquisition +23,931 $15.67
2026-06-01 Tang Capital Management, LLC -- Open Market Acquisition +814,606 $15.28–15.35
2026-06-01 Tang Capital Management, LLC -- Other Derivative Acquisition +10,000 $15.00
2026-06-01 Gregory Keenan Chief Medical Officer Intent to Sell (Form 144) -25,000 $2,164.00
2026-05-17 Michael Hearne Chief Financial Officer Other Acquisition +116,144 --
2026-05-17 Michael Hearne Chief Financial Officer Other Derivative Acquisition +70,230 $15.28
2026-05-17 Ryan Cole Chief Operating Officer Other Acquisition +116,144 --
2026-05-17 Ryan Cole Chief Operating Officer Other Derivative Acquisition +70,230 $15.28
2026-05-17 Stephen Robertson Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer Other Acquisition +115,541 --
2026-05-10 Peter Greenleaf Chief Executive Officer Intent to Sell (Form 144) -3,136,201 $15.84
2026-05-10 Joseph Miller Chief Financial Officer Intent to Sell (Form 144) -500,503 $15.84
2026-03-05 Gregory Keenan Chief Medical Officer Sale to Issuer -8,069 $14.32
2026-03-02 Tang Capital Management, LLC -- Open Market Acquisition +898,400 $13.90–14.33

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-10-08 08:17:43 · For reference only, not investment advice and not tailored to your situation.